He Lvfu, Zhan Lisha, Yang Yu, He Weimin
Department of Ophthalmology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, China.
Front Immunol. 2025 Feb 18;16:1514003. doi: 10.3389/fimmu.2025.1514003. eCollection 2025.
This study aimed to investigate the expression condition of a proliferation-inducing ligand (APRIL) in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases (IgG4-ROD) and mucosa-associated lymphoid tissue (MALT) lymphoma.
Fifteen patients with IgG4-ROD, 3 with MALT lymphoma, and 1 with elevated IgG4 with lacrimal gland lesions, treated in West China Hospital of Sichuan University from April 2022 to November 2023, were included. Immunofluorescence staining was used to detect the expression of APRIL in the specimen of lacrimal gland.
The average expression level of APRIL in patients with lacrimal gland lesions of IgG4-ROD and MALT lymphoma were 8471.12 pixels/HPF and 2950.78 pixels/HPF respectively. The positive rates of APRIL were 10.49% and 7.23% respectively. CD138 and APRIL were colocalized, and the positive rate of their colocalization was 8.83%, and the positive areas of colocalization coincidence was 946.84 pixels/HPF in patients with IgG4-ROD. CD20 and APRIL were colocalized, and the positive rate of their colocalization was 7.04%, and the positive areas of colocalization coincidence was 949.78 pixels/HPF in patients with MALT lymphoma. We also found that the expression level and the positive rate of APRIL were positively correlated with the level of serum IgG4 in IgG4-ROD patients (r=0.5820, =0.029; r= 0.6261, =0.017; respectively). In addition, the positive rate and the positive areas of CD138 and APRIL colocalization were also positively correlated with serum IgG4 level (r=0.6420, =0.013; r= 0.5673, =0.034; respectively).
APRIL is highly expressed in lacrimal gland lesions of patients with IgG4-ROD and MALT lymphoma. This overexpression may facilitate the enrichment of CD138 plasma cells and is associated with elevated serum IgG4 levels in patients with IgG4-ROD. Additionally, it may promote the proliferation of CD20 B lymphocytes in patients with MALT lymphoma.APRIL may play a certain role in the possible transformation of IgG4-ROD into MALT lymphoma.
本研究旨在探讨增殖诱导配体(APRIL)在IgG4相关眼病(IgG4-ROD)和黏膜相关淋巴组织(MALT)淋巴瘤患者泪腺病变中的表达情况。
纳入2022年4月至2023年11月在四川大学华西医院接受治疗的15例IgG4-ROD患者、3例MALT淋巴瘤患者以及1例IgG4升高伴泪腺病变的患者。采用免疫荧光染色法检测泪腺标本中APRIL的表达。
IgG4-ROD和MALT淋巴瘤泪腺病变患者中APRIL的平均表达水平分别为8471.12像素/高倍视野(HPF)和2950.78像素/HPF。APRIL的阳性率分别为10.49%和7.23%。在IgG4-ROD患者中,CD138与APRIL共定位,其共定位阳性率为8.83%,共定位阳性面积为946.84像素/HPF。在MALT淋巴瘤患者中,CD20与APRIL共定位,其共定位阳性率为7.04%,共定位阳性面积为949.78像素/HPF。我们还发现,IgG4-ROD患者中APRIL的表达水平和阳性率与血清IgG4水平呈正相关(r分别为0.5820,P = 0.029;r为0.6261,P = 0.017)。此外,CD138与APRIL共定位的阳性率和阳性面积也与血清IgG4水平呈正相关(r分别为0.6420,P = 0.013;r为0.5673,P = 0.034)。
APRIL在IgG4-ROD和MALT淋巴瘤患者的泪腺病变中高表达。这种过表达可能促进CD138浆细胞的富集,并与IgG4-ROD患者血清IgG4水平升高有关。此外,它可能促进MALT淋巴瘤患者CD20 B淋巴细胞的增殖。APRIL可能在IgG4-ROD向MALT淋巴瘤的可能转变中起一定作用。